Clinical manifestations and prevalence of hypercoagulable states in patients with venous thromboembolic disease;Características clínicas y prevalencia de los estados de hipercoagulabilidad en pacientes con enfermedad tromboembólica venosa

Medicina Clinica

Volumn 116, Issue 6, 2001, Pages 201-205

  Briones, Andrés ^a   Nauffal, Dolores ^a   Villa, Piedad ^a   Martínez, Miguel Ángel ^a   Menéndez, Rosario ^a   Perpiñá, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Hypercoagulables states; PAI 1; Pulmonary embolism; Thrombophilia; Venous thromboembolic disease

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; FEMALE; HUMAN; LUNG EMBOLISM; MALE; METABOLISM; MIDDLE AGED; PREVALENCE; SPAIN; THROMBOPHILIA; VEIN THROMBOSIS;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREVALENCE; PULMONARY EMBOLISM; SPAIN; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0040754522     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71771-x     Document Type: Article

References (26)

1. Rosemberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-1564.
2. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119: 819-827.
3. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J, and the EMET Group. Laboratory evaluation and clinical characteristics of 2132 consecutive unselected patients with venous thromboembolism. Results of the Spanish multicentric study of thrombophilia (EMET study). Thromb Haemost 1997; 77: 754-760.
4. Benedicto E, Yuste JR, Páramo JA, Rocha E, Prieto J. Prevalencia de los estados de hipercoagulabilidad en pacientes con trombosis en Navarra Septentrional. An Med Interna (Madrid) 1997; 14: 450-454.
5. The PIOPED investigators. Value of the ventilation-perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis. JAMA 1990; 263: 2753-2759.
6. Tollefsen DM, Pestka CA, Monafo WJ. Activation of cofactor II by dermatan sulphate. J Biol Chem 1983; 258: 6713-6716.
7. Jorquera JI, Montoro JM, Fernández MA, Aznar JA. Modified test for activated protein C. Lancet 1994; 344: 1162-1163.
8. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coagul Fibrinol 1995; 6: 245-247.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gen is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
10. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 651-662.
11. Tait RC, Walker ID, Perry DJ, Islam SIAM, Daly ME, McCall F et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-112.
12. Tait RC, Walker ID, Reistma PH, Islam SIAM, McCall F, Poort SR et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemostas 1995; 73: 87-93.
13. Souto JC, Coll I, Llobet D, Del Río E, Oliver A, Mateo J et al. The prothrombin 20210 A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population Thromb Haemostas 1998; 80: 366-359.
14. Otero R, Arenas M, Hurtado JE, Morales R, Monedero M, Digón J. Búsqueda de marcadores clínicos de hipercoagulabilidad patológica según los factores desencadenantes de enfermedad tromboembólica venosa. Arch Bronconeumol 1999; 35: 329-333.
15. Koster T, Rosendaal FR, Ronde H, Briet E, Vandebroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
16. Malm J, Nilssor JM, Dahlback B. Thromboembolic disease. Critical evaluation of laboratory investigation. Thromb Haemostas 1992; 68: 7-13.
17. Lane DA, Southam C. Inherited abnormalities of fibrinogen synthesis and structure. En: Bloom AL, Thomas DP, editores. Haemostasis and thrombosis. Edimburgo: Churchill Livingstone, 1987; 442-460
18. Rocna E, Alfaro MJ, Páramo JA, Cañadell J. Preoperative identification of patients a: high risk of deep venous thrombosis despite prophylaxis in total hip replacement. Thromb Haemostas 1988; 59: 93-95.
19. Bick RL, Ancypa D. The antiphospholipid and thrombosis syndromes. Clin Lab Med 1995; 15: 63-84.
20. Cattaneo M. Hyperhomocystinemia, atherosclerosis and thrombosis. Thromb Haemostas 1999; 81: 165-176.
21. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Poris MH et al. The risk of recurrent venous thromboembolism in patients with an Arg 506- G n mutation in the gene for factor V (factor V Leiden) N Engl J Med 1997; 336: 399-403
22. Schulman S, Granovist S, Helmstrom M, Carlsson A, Lindmarker P, Nico P et al. The duration of oral anticoagulation after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-398.
23. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114 (Supl): 561-578.
24. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Bouyjenkov V et al. Inherited thrombophilia: part 2. Thromb Haemostas 1996; 76: 824-834.
25. Fernández del Rivero TP. Casos clinicos con patologia tromboembólica. Enfermedad tromboembolica en el paciente oncológico. Barcelona: Doyma S.A., 1996.
26. Garcia de Tena J, De Miguel Diez J, Serrano Iglesias JA. ¿Son necesarias las pruebas de cribado para la detección de estados de hipercoagulabilidad ante situaciones de riesgo para feriómeros tromboembólicos? Med Clin (Barc) 1997; 8: 197